Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease TUMMY trial
Latest Information Update: 27 Aug 2021
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TUMMY
- 27 Aug 2021 New trial record